Navigation Links
Access Pharmaceuticals Provides Update on Global Launch of MuGard(TM)
Date:5/27/2009

NEW FDA-APPROVED TREATMENT FOR ORAL MUCOSITIS

DALLAS, May 27 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), (http://www.accesspharma.com) announced today that MuGard(TM), its proprietary oral mucositis product has been launched in Germany, Italy, UK, Greece and the Nordic countries by its European commercial partner, SpePharm, a pan-European specialty pharmaceutical company dedicated to the provision of high medical value medicines in supportive and critical care. The Company has previously announced commercialization agreements in North America, China and eight Southeast Asian countries and Korea, and is actively seeking additional marketing partners in other regions; MuGard expects commercial launches in these regions throughout the remainder of 2009 as manufacturing and reimbursement gets established regionally.

MuGard is a ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Up to 40% of all patients receiving chemotherapy and/or radiation therapy develop moderate to severe mucositis, and almost all patients receiving radiotherapy for head and neck cancer and those undergoing stem cell transplantation develop mucositis. Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatment of oral mucositis is estimated to be in excess of $1 billion world-wide.

"Access is pleased with the commercial launch of MuGard in Europe, and the progress made by our partners in other regions of the world," said Phillip Wise, Vice President of Business Development at Access. "Access is also working with its partners outside of Europe to establish GMP manufacturing and secure necessary approvals and/or reimbursement from the individual governmental regulators, which we believe will greatly enhance initial product adoption and ongoing marketing efforts to reach and penetrate the target population of patients requiring this important treatment option," he continued.

MuGard forms a protective coating over the oral mucosa when swirled gently around the mouth. In a comparison of cancer patients receiving standard mucositis care with those patients receiving MuGard, the incidence and severity of mucositis was significantly lower in the MuGard treated group using a validated scale for the assessment of oral mucositis.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; and Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer. Access recently announced completed the acquisition of MacroChem Corporation. This acquisition provides Access with Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for ProLindac and other product candidates, our ability to execute licensing agreements in the future, Access' plans to continue and initiate clinical trials, the value of its products in the market (including MuGard and the size of the overall market for mucositis products), its ability to achieve clinical and commercial success and its ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.


'/>"/>
SOURCE Access Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. GAO Report Confirms: Medicare Underpays for Anesthesia Services; Nurse Anesthetists Assure Seniors Access to Safe Anesthesia Care
2. Report on patients access to cancer drugs uses flawed methods to reached flawed conclusions
3. Open access to health research publications
4. Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic, Debilitating and Life-Threatening Illness Access Quality Healthcare
5. Care reforms raise concerns over patient access to GP services
6. Access Innovations Provides Support Services for Agis Network
7. RAND researchers offer options to improve immigrant health care quality, access
8. Uninsured community health center patients often have difficulty accessing specialty services
9. Hispanics hypertension better controlled with equal access to care
10. PA Health Department Survey Shows Impact of Income, Gender, Other Factors on Health and Access to Health Care
11. More than 10,000 Medicare Patients in Montana Could Be Hit by Proposed Cuts to Home Oxygen Therapy; Access to Power Wheelchairs Would Also Decrease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... Lewisville, Texas (PRWEB) , ... May 30, 2016 , ... ... at 7 am in Plano, located at 3960 Legacy Drive, Plano, TX and is ... the Plano Chamber of Commerce followed by a medical open house. The Jasper High ...
(Date:5/29/2016)... ... ... "With 30 unique self-animating web themed intros and complete control over customization, ... Christina Austin - CEO of Pixel Film Studios. , ProIntro Web Volume 3 ... Cut Pro X. Pixel Film Studios’ minimalistic titles allow users to add a sleek ...
(Date:5/28/2016)... ... , ... May 26, 2016- In search of the K. Warriors, Shaolin Institute ... “K Warriors” on June 4, 2016 at Ashbury Hotel and Suites 600 West Interstate ... hosted by Shaolin Institute and sanctioned by KSF (Kungfu Sanda Federation), This is the ...
(Date:5/27/2016)... ... May 27, 2016 , ... More than a third of American adults are ... bariatric surgery has received increased attention in recent years, as an article ... to weight loss, most people are familiar with the basic requirements of maintaining a ...
(Date:5/27/2016)... , ... May 27, 2016 , ... W.S. Badger ... announced today that it has been recognized as one of the best small businesses ... was named as one of nine small businesses providing progressive benefits to new parents ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... 25, 2016  Granger Diagnostics today announced immediate availability ... and infections. This test ensures discovery of ALL ... The test requires only a simple swab of the ... David G. Bostwick , MD, Chief Medical Officer, ... healing: "We are excited to make available, for ...
(Date:5/25/2016)... ReportsnReports.com adds "Chronic Cough ... provides an overview on therapeutic pipeline of Chronic ... therapeutics assessment by drug target, mechanism of action ... along with latest updates, and featured news and ... in the therapeutic development for Chronic Cough and ...
(Date:5/24/2016)... , May 24, 2016   ... endpoints demonstrating non-inferiority in overall bowel cleansing and superiority ... c leansing of the ... http://photos.prnewswire.com/prnh/20130829/633895-a ) , Norgine B.V. today announced new ... litre PEG and ascorbate bowel preparation) versus standard 2 litre PEG ...
Breaking Medicine Technology: